Aphria, ODI Pharma execute supply agreement

ODI Pharma | November 03, 2020

Aphria, ODI Pharma execute supply agreement
ODI Pharma AB today announced that, despite COVID 19 delays, it has streamlined its supply chain and executed a Supply Agreement (the "Supply Agreement") with Aphria Inc.'s ("Aphria") (TSX: APHA) (Nasdaq: APHA) wholly-owned German subsidiary, CC Pharma GmbH ("CC Pharma"). The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward.

The highlights of the Supply Agreement are:

The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names;

The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and
CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland.

Aphria Inc. Chief Executive Officer and Chairman, Irwin D. Simon comments

"We are pleased to announce our partnership with ODI Pharma, which expands the international presence of our Aphria medical brand into Poland. This partnership is further evidence of our global commitment to provide patients with access to high-quality medical cannabis products as well as a testament to the strength and quality of our medical brand, Aphria.  We look forward to working with ODI Pharma in bringing our high-quality medical cannabis products to patients in Poland."

ODI Pharma AB CEO Derek Simmross comments
"We are pleased to continue our relationship with Aphria through our new partnership between CC Pharma and ODI Pharma. We see that this will contribute to our operational efficiency and it is exciting to further advance the terms of our relationship to include a broader product offering. Our goal remains to represent the best and most technologically advanced producer of medical cannabis in the industry for the Polish people."

ODI Pharma AB Chairman Volker Wiederrich comments

"We are proud of our partnership with CC pharma, a global leader who shares with us the same quality values and commitments of meeting patients' needs and improving their quality of life. Also, this is another vote of confidence in ODI Pharma's leadership and the Polish medical cannabis market."

About ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. ODI will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

About Aphria Inc.

Aphria Inc. is a leading global cannabis company inspiring and empowering the worldwide community to live their very best life. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. Aphria's portfolio of brands is grounded in expertly researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders' multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.

Spotlight

A line integrated alu-alu blister packing, cartoning, weighing and Stretch-Banding

Related News

National Healthcareer Association (NHA) Launches Coalition for the Advancement of Pharmacy Technician Practice

Prnewswire | August 20, 2020

The National Healthcareer Association (NHA) has formed a unique, nationwide Pharmacy Technician Coalition. The coalition is focused solely on bringing pharmacy technician organizations, industry leaders, and associations together to advocate for and implement changes to expand the role of certified pharmacy technicians (CPhT), allowing them to help with needs during COVID-19. As pharmacies continue to provide more direct patient care services and are faced with increased workload during the pandemic, CPhTs have an opportunity to help with some of the pharmacists' duties, to be more efficient in delivering patient care.

Read More

PHARMACY MARKET

Transaction Data Systems Achieves KloudScript, A Cloud-Based Specialty Pharmacy Solution

Transaction Data Systems | November 25, 2020

Exchange Data Systems (TDS), the pioneer in drug store programming answers for the network drug store market, today reported the obtaining of KloudScript, a strength drug store care arrangement. Right now 39% of network drug stores apportion a type of strength prescriptions, agreeing the National Community Pharmacy Association. Interest for strength meds has been consistently ascending to treat explicit sickness states and the constantly sick. With the maturing populace and the expansion in ongoing consideration, forte drug store is required to develop to $500 billion as strength meds arrive at half of outpatient drug spend by end of 2020. “Combining KloudScript’s capabilities with our market-leading solutions will empower our pharmacists to expand into specialty medication offerings,” said Jude Dieterman, CEO of TDS. “This acquisition further cements TDS’s leadership position in the independent pharmacy market and demonstrates our commitment to delivering the most clinically focused solution suite for community pharmacy.” The increase in specialty medications has caused a shift in distribution and dosage form from traditional injectable and infusible formulations to oral dosage. At the end of 2019, 60% of the new drugs awaiting FDA approval were specialty medications with a noteworthy number in oral dosage form. The growth of specialty drugs and the shift to oral medications has opened a path for patient-focused pharmacists to further distinguish themselves through coordinated care of chronic disease states. “We are excited to bring Kloudscript into the TDS suite of solutions and services,” stated Rinku Patel, Pharm D, KloudScript CEO and Founder. “Together we look forward to bringing innovative service solutions to our pharmacy, pharma, payor and prescriber partners that solve the accessibility, affordability and adherence challenges of patient care.”

Read More

PHARMACY MARKET

Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020

Ascentage Pharma | January 05, 2021

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FDA, following the past ODDs for the therapy of Waldenström macroglobulinemia (WM), ongoing lymphocytic leukemia (CLL), and numerous myeloma (MM). Until this point, four of Ascentage Pharma's investigational drug up-and-comers have been allowed an aggregate of nine ODDs by the US FDA, a record number for any Chinese biopharmaceutical organization. AML is an exceptionally heterogenous hematologic threat that is more normal in the old populace with a middle age at analysis of 68 years1. The latest information from the Surveillance, Epidemiology, and End Results Program (SEER) of the US National Cancer Institute (NCI) assessed 19,940 new instances of AML and 11,180 passings from this infection in the United States in 2020. Notwithstanding the critical advances in therapeutics as of late, the 5-year endurance pace of AML stays at 25%–30%, which actually speaks to a huge neglected clinical requirement for treatments with more solid viability and a superior wellbeing profile. The expression "vagrant medications" alludes to drug items produced for the counteraction, finding, and treatment of uncommon illnesses or conditions. In the United States, a vagrant sign is characterized as a sickness or condition with a pervasiveness of under 200,000 patients in the nation. Since the Orphan Drug Act was passed in 1983, the US government has given motivators and strategy backing to support advancement of vagrant medications. Treatments conceded ODDs by the FDA are equipped for different advancement motivators, including a tax break on consumptions brought about in clinical examinations, a waiver of the New Drug Application (NDA) charge, conceivable exploration award granted by the FDA, and above all, 7 years of US market restrictiveness upon endorsement.

Read More

Spotlight

A line integrated alu-alu blister packing, cartoning, weighing and Stretch-Banding